RedHill Biopharma Ltd RDHL shares are trading higher after the company said that its oral opaganib shows a significant increase in survival time (at 150 mg/kg twice daily dose) in a U.S. Army-funded in vivo Ebola virus study, making it the first host-directed molecule to show activity in the Ebola virus disease.
"These results represent an alternative strategy of using a host-directed therapeutic with activity in Ebola virus disease in-vivo," said Rekha Panchal, who led the study.
The U.S. Army study tested three doses of opaganib (50, 100, and 150 mg/kg twice daily) against an inactive vehicle control arm.
The in vivo study results showed a statistically significant survival increase in mean (SE) survival time of 11.2 (2.6) days in the 150 mg/kg opaganib group (p=0.0279) compared to a mean (SE) survival time of 5.5 (0.4) days in the inactive vehicle control group.
A 30% mice survival was observed in the 150 mg/kg treated group compared to the vehicle control.
Twice daily administered opaganib has previously demonstrated antiviral benefit in late-stage clinical studies of patients hospitalized with moderate to severe COVID-19 and was selected by the NIH Radiation and Nuclear Countermeasures Program for Acute Radiation Syndrome development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.